Temasek’s venture capital arm Vertex Ventures has participated in a $47.6 million Series A financing round in Palleon Pharmaceuticals, a US-based biotechnology firm that focuses on developing glycoimmune checkpoint inhibitors to treat cancer.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
